neflamapimod

Phase 2Small molecule

EEIP Pharma Inc

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Progressive AphasiaActive, not recruiting

Primary Progressive AphasiaPhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Primary Progressive Aphasia

NCT07033481

Phase 2Active, not recruiting

Ischaemic Stroke

NCT06987643

Clinical

Trials by Indication[1]

Dementia With Lewy Bodies2 trials

A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies

Completed·EEIP Pharma Inc·Phase 2·NCT05869669·159 enrolled

An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)

Completed·EEIP Pharma Inc·Phase 2·NCT06815965·26 enrolled

Alzheimer's Disease1 trial

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease

Completed·EEIP Pharma Inc·Phase 2·NCT03402659·161 enrolled

Dementia1 trial

Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies

Completed·EEIP Pharma Inc·Phase 2·NCT04001517·91 enrolled

Huntington disease1 trial

Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease

Terminated·EEIP Pharma Inc·Phase 2·NCT03980938·15 enrolled

Ischaemic Stroke1 trial

A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke

Active, not recruiting·EEIP Pharma Inc·Phase 2·NCT06987643·90 enrolled

1 more indication

Primary Progressive Aphasia1 trial

A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)

Active, not recruiting·EEIP Pharma Inc·Phase 2·NCT07033481·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for neflamapimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — neflamapimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for neflamapimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — EIP Pharma Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEIP Pharma Inc